

References

R-18

1. Adeberg S, Harrabi SB, Bougatf N, et al. Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma: a dosimetric comparison. *Strahlenther Onkol.* 2016;192(11):770-779.
2. Allen AM, Pawlicki T, Dong L, et al. An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee. *Radiother Oncol.* 2012;103(1):8-11.
3. American Society for Radiation Oncology Model Policies. Proton Beam Therapy (PBT). 2017 June.
4. Amichetti M, Amelio D, Cianchetti M, et al. A systematic review of proton therapy in the treatment of chondrosarcoma of the skull base. *Neurosurg Rev.* 2010;33(2):155-165.
5. Amichetti M, Cianchetti M, Amelio D et al. Proton therapy in chordoma of the base of the skull: a systematic review. *Neurosurg Rev.* 2009;32(4):403-16.
6. Arvold ND, Niemierko A, Broussard GP, et al. Projected second tumor risk and dose to neurocognitive structures after proton versus photon radiotherapy for benign meningioma. *Int J Radiat Oncol Biol Phys.* 2012 Jul 15;83(4):e495-e500. Accessed April 17, 2018
7. ASTRO Model Policies. Proton Beam Therapy (PBT). Approved May 20, 2014. Pages 1-15. Accessed April 5, 2018.
8. ASTRO Position Statement. Use of proton beam therapy for prostate cancer. 2013 Feb. Accessed April 10, 2018.
9. ASTRO release list of five radiation oncology treatments to question as part of national Choosing Wisely® campaign. 2013 Sep 13.
10. Athar BS, Paganetti H. Neutron equivalent doses and associated lifetime cancer incidence risks for head & neck and spinal proton therapy. *Phys Med Biol.* 2009;54(16):4907-4926.
11. Barker FG 2nd, Butler WE, Lyons S, et al. Dose-volume prediction of radiation-related complications after proton beam radiosurgery for cerebral arteriovenous malformations. *J Neurosurg.* 2003;99(2):254-263.
12. Bekelman JE, Schultheiss T, Berrington De Gonzalez A. Subsequent malignancies after photon versus proton radiation therapy. *Int J Radiat Oncol Biol Phys.* 2013;87(1):10-12.
13. Berrington de Gonzalez A, Gilbert E, Curtis R, et al. Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. *Int J Radiat Oncol Biol Phys.* 2013;86(2):224-233.
14. Bhattasali O, Holliday E, Kies MS, et al. Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: a series of 9 cases and a critical review of the literature. *Head Neck.* 2016 Apr;38(S1):E1472-E1480. Accessed April 9, 2018.
15. Boskos C, Feuvret L, Noel G, et al. Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. *Int J Radiat Oncol Biol Phys.* 2009;75(2): 399-406.
16. Brenner DJ, Hall EJ. Secondary neutrons in clinical proton radiotherapy: a charged issue. *Radiother Oncol.* 2008;86(2):165-70.

17. Bradley JA, Dagan R, Ho, MW, et al. Initial report of a prospective dosimetric and clinical feasibility trial demonstrates the potential of protons to increase the therapeutic ratio in breast cancer compared with photons. *Int J Radiat Oncol Biol Phys*. 2016 May 1;95(1):411-421. Accessed April 5, 2018.
18. Bush DA, McAllister CJ, Loreda LN et al. Fractionated proton beam radiotherapy for acoustic neuroma. *Neurosurgery*. 2002;50(2): 270-275.
19. Cella L, Conson M, Pressello MC, et al. Hodgkin's lymphoma emerging radiation treatment techniques: trade-offs between late-night radio-induced toxicities and secondary malignant neoplasms. *Radiat Oncol*. 2013 Dec;8:22. Accessed April 17, 2018.
20. Chan AW, Liebsch NJ. Proton radiation therapy for head and neck cancer. *J Surg Oncol*. 2008;97(8):697-700.
21. Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. *Cancer*. 2011;117(20):4707-4713.
22. Chang JY, Verma V, Li M, et al. Proton beam radiotherapy and concurrent chemotherapy for unresectable Stage III non-small cell lung cancer. *JAMA Oncol*. 2017 Aug;3(8):e172032. Accessed April 6, 2018.
23. Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2005 Jul 15;65(4):1087-1096. Accessed April 6, 2018.
24. Char DH, Kroll S, Phillips TL, et al. Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. *Ophthalmology*. 2002;109(10):1850-1854.
25. Chera BS, Rodriguez C, Morris CG, et al. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. *Int J Radiat Oncol Biol Phys*. 2009 Nov 15;75(4):1173-1180. Accessed April 17, 2018.
26. Chung CS, Yock TI, Nelson K, et al. Incidence of second malignancies among patients treated with proton versus photon radiation. *Int J Radiat Oncol Biol Phys*. 2013;87(1):46-52.
27. ClinicalTrials.gov. A Phase I/II study of hypofractionated proton therapy for Stage II-III non-small cell lung cancer. NCT01770418, Last updated January 18, 2018. Accessed April 6, 2018.
28. ClinicalTrials.gov. Comparing photon therapy to proton therapy to treat patients with lung cancer. NCT01993810, Last updated June 13, 2016.
29. ClinicalTrials.gov. Glioblastoma multiforme (GBM) proton vs. intensity modulated radiotherapy (IMRT). NCT01854554, Last updated August 15, 2017.
30. ClinicalTrials.gov. Hypofractionated image guided proton therapy for low and intermediate risk prostate cancer. NCT02040610, Last updated February 27, 2018. Accessed April 11, 2018.
31. ClinicalTrials.gov. Hypofractionated proton beam therapy for localized prostate cancer. NCT01950351, Last updated February 23, 2018. Accessed April 11, 2018.
32. ClinicalTrials.gov. Intensity-modulated scanning beam proton therapy (IMPT) with simultaneous integrated boost (SIB). NCT01629498, Last updated December 5, 2017.

33. ClinicalTrials.gov. Hypo-fractionated radiation therapy with or without androgen suppression for intermediate risk prostate cancer. NCT01492972, Last updated January 18, 2018. Accessed April 11, 2018.
34. ClinicalTrials.gov. In-room PET in proton radiation therapy. NCT01228448, Last updated March 8, 2018. Accessed April 11, 2018.
35. ClinicalTrials.gov. Mild hypofractionation with proton therapy or intensity modulated radiation therapy (IMRT) for intermediate-risk prostate cancer. NCT01352429, Last updated September 26, 2016. Accessed April 11, 2018.
36. ClinicalTrials.gov. Prospective evaluation of hypofractionation proton beam therapy with concurrent treatment of the prostate and pelvic nodes for clinically localized, high risk or unfavorable intermediate risk prostate cancer. NCT02874014, Last updated October 24, 2017. Accessed April 11, 2018.
37. ClinicalTrials.gov. Proton beam radiation therapy and chemotherapy in treating patients with Stage III non-small cell lung cancer that can be removed by surgery. NCT01076231, Last updated April 13, 2016.
38. ClinicalTrials.gov. Proton radiation therapy in treating patients with prostate cancer. NCT01045226, Last updated September 26, 2016. Accessed April 11, 2018.
39. ClinicalTrials.gov. Proton radiotherapy for stage I, IIA, and IIB seminoma, NCT01557790, Last Updated September 23, 2016.
40. ClinicalTrials.gov. Proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung cancer (PRONTOX). NCT02731001. Last updated September 14, 2017. Accessed April 6, 2018.
41. ClinicalTrials.gov. Proton therapy vs. IMRT for low or intermediate risk prostate cancer (PARTIQoL). NCT01617161, Last updated February 26, 2018. Accessed April 11, 2018.
42. ClinicalTrials.gov. Study of hypofractionated proton beam radiation therapy for prostate cancer. NCT00831623, Last updated April 6, 2018. Accessed April 11, 2018.
43. ClinicalTrials.gov. Study of hypo-fractionated proton radiation for low risk prostate cancer. NCT01230866, Last updated January 18, 2018. Accessed April 11, 2018.
44. Coen JJ, Bae K, Zietman AL, et al. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03- 12. *Int J Radiat Oncol Biol Phys*. 2011;81(4):1005-1009.
45. Coen JJ, Paly JJ, Niemierko A, et al. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2012 Feb 1;82(2):e201-209. Accessed April 10, 2018.
46. Coeh JJ, Zietman AL, Rossi CJ, et al. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. *Int J Radiat Oncol Biol Phys*. 2012 Jan 1;82(1):e25-e31. Accessed April 10, 2018.
47. Conway RM, Poothullil AM, Daftari IK, et al. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy. *Arch Ophthalmol*. 2006;124(6):838–843.
48. Cuaron JJ, Chon B, Tsai H, et al. Early toxicity in patients treated with postoperative proton therapy for locally advanced breast cancer. *Int J Radiat Oncol Biol Phys*. 2015 Jun 1;92(2):284-291. Accessed April 5, 2018.

49. Debus J, Schulz-Ertner D, Schad L, et al. Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base. *Int J Radiat Oncol Biol Phys*. 2000;47(3):591-596.
50. Dědečková, K, Móciková, H, Marková, J, et al. T011: Proton radiotherapy for mediastinal Hodgkin lymphoma: single institution experience (abstract). *Haematologica*. 2016;101(Suppl 5):12-13. Accessed April 17, 2018.
51. Dennis ER, Bussière MR, Niemierko A, et al. A comparison of critical structure dose and toxicity risks in patients with low grade gliomas treated with IMRT versus proton radiation therapy. *Tech Cancer Res Treat*. 2013 Feb 1;12(1):1-9. Accessed April 5, 2018.
52. Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, et al. Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients. *Ophthalmic Res*. 2006;38(5):255–260.
53. Eaton BR, MacDonald SM, Yock TI, et al. Secondary malignancy risk following proton radiation therapy. *Front Oncol*. 2015;5:261.
54. Efstathiou JA, Trofimov AV, Zietman AL. Life, liberty, and the pursuit of protons: an evidence-base review of the role of particle therapy in the treatment of prostate cancer. *The Cancer J*. 2009;15(4):312-318.
55. Egger E, Zografos L, Schalenbourg A, et al. Eye retention after proton beam radiotherapy for uveal melanoma. *Int J Radiat Oncol Biol Phys*. 2003;55(4):867-880.
56. Esmaeli B, Yin VT, Hanna EY, et al. Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma. *Head Neck*. 2016 Aug;38(8):1258-1262. Accessed April 9, 2018.
57. Fang P, Mick R, Deville C, et al. A case-matched study of toxicity outcomes after proton therapy and intensitymodulated radiation therapy for prostate cancer. *Cancer*. 2015 Apr 1;121(7):1118-1127. Accessed April 10, 2018.
58. Filippi AR, Ciammella P, Piva C, et al. Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma. *Int J Radiat Oncol Biol Phys*. 2014 Jun 1;89(2):370-375. Accessed April 17, 2018.
59. Fitzek MM, Thornton AF, Harsh GT, et al. Dose-escalation with proton/photon irradiation for Dumas-Duport lower-grade glioma: results of an institutional phase I/II trial. *Int J Radiat Oncol Biol Phys*. 2001;51(1):131- 137.
60. Fitzek MM, Thornton AF, Rabinov JD, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. *J Neurosurg*. 1999;91(2):251- 260.
61. Fukumitsu N, Sugahara S, Nakayama H, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2009;74(3):831-836.
62. Funk RK, Tryggstad EJ, Kazemba BD, et al. Dosimetric comparison of IMRT vs. pencil-beam scanning proton therapy for distal esophageal cancer. Proceedings to the 54th Annual Meeting for the Particle Therapy Cooperative Group (PTCOG) and the 2nd Annual Meeting of PTCOG- North America. *Int J Particle Therapy*. 2015 Summer;2(1): 360-361. Accessed April 6, 2018.
63. Georg D, Hopfgartner J, Gøra J, et al. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or

low-dose-rate brachytherapy. *Int J Radiat Oncol Biol Phys*. 2014 Mar 1;88(3):715-722. Accessed April 10, 2018.

64. Gray PJ, Paly JJ, Yeap BY, et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. *Cancer*. 2013 Jan 1;119(9):1729-1735. Accessed April 10, 2018.

65. Greenberger BA, Pulsifer MG, Ebb DH, et al. Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas. *Int J Radiat Oncol Biol Phys*. 2014 Aug 1;89(5):1060-1068. Accessed April 5, 2018.

66. Grutters JPC, Kessels AGH, Pijls-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. *Radiother Oncol*. 2010;95(1):32-40.

67. Gunn GB, Blanchard P, Garden AS, et al. Clinical outcomes and patterns of disease recurrence after intensity modulated proton therapy for oropharyngeal squamous carcinoma. *Int J Radiat Oncol Biol Phys*. 2016 May 1;95(1):360-367. Accessed April 9, 2018.

68. -Harrabi SB, Bougatf N, Mohr A, et al. Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma. *Strahlenther Onkol*. 2016 Nov;192(11):759-769. Accessed April 5, 2018.

69. Hasegawa T, Ishii D, Kida Y, et al. Gamma Knife surgery for skull base chordomas and chondrosarcomas. *J Neurosurg*. 2007;107(4):752-757.

70. Hashimoto T, Tokuyue K, Fukumitsu N, et al. Repeated proton beam therapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2006;65(1):196-202.

71. Hata M, Tokuyue K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. *Strahlenther Onkol*. 2006;182(12):713-720.

72. Hata M, Tokuyue K, Sugahara S et al. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. *Cancer*. 2005;104(4):794-801.

73. Hauswald H, Rieken S, Ecker S, et al. First experiences in treatment of low-grade glioma grade I and II with proton therapy. *Radiation Oncol*. 2012 Dec;7:189. Accessed April 5, 2018.

74. Holliday E, Bhattasali O, Kies M, et al. Postoperative intensity-modulated proton therapy for head and neck adenoid cystic carcinoma. *Int J Particle Ther*. 2016 Spring;2(4):543-543. Accessed April 9, 2018.

75. Holiday EB, Esmali B, Pinckard J, et al. A multi-disciplinary approach that includes proton therapy for epithelial tumors of the orbit and ocular adnexa. *Int J Radiat Oncol Biol Phys*. 2016 May 1;95(1):344-352. Accessed April 9, 2018.

76. Holliday EB, Frank SJ. Proton radiation therapy for head and neck cancer: a review of the clinical experience to date. *Int J Radiat Oncol Biol Phys*. 2014;89(2):292-302.

77. Holliday EB, Garden AS, Rosenthal DI, et al. Proton therapy reduces treatment-related toxicities for patients with nasopharyngeal cancer: a case-match control study of intensity-modulated proton therapy and intensity-modulated photon therapy. *Int J Particle Ther*. 2015 Summer;2(1):19-28. Accessed April 9, 2018.

78. Holliday EB, Kocak-Uzel E, Feng L, et al. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: a case-matched control analysis. *Med Dosim*. 2016 Autumn;41(3):189-194. Accessed April 9, 2018.

79. Hoppe BS, Flampouri S, Henderson RH, et al. Proton therapy with concurrent chemotherapy for non-small-cell lung cancer: technique and early results. *Clin Lung Cancer*. 2012;13(5):352-358.
80. Hoppe BS, Flampouri S, Zaiden R, et al. Involved-node proton therapy in combined modality therapy for Hodgkin's lymphoma: results of a phase 2 study. *Int J Radiat Oncol Biol Phys*. 2014 Aug 1;89(5):1053-1059. Accessed April 17, 2018.
81. Hoppe BS, Mamalui-Hunter M, Mendenhall NP, et al. Improving the therapeutic ratio by using proton therapy in patients with stage I or stage II seminoma. *Am J Clin Oncol*. 2013;36(1):31-37.
82. Hoppe BS, Michalski JM, Mendenhall NP, et al. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. *Cancer*. 2014;120(7):1076-1085.
83. Hoppe BS, Tsai H, Larson G, et al. Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry. *Acta Oncol*. 2016;55(11):1278-1380. Accessed April 17, 2018.
84. Horn S, Fournier-Bidoz N, Pernin V, et al. Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy. *Cancer Radiother*. 2016 Apr;20(2):98-103. Accessed April 17, 2018.
85. Horwich A, Fossa SD, Huddart R, et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. *Brit J Cancer*. 2014;110 (1): 256-263.
86. Hsiung-Stripp DC, McDonough J, Masters HM, et al. Comparative treatment planning between proton and xray therapy in pancreatic cancer. *Med Dosim*. 2001;26(3):255-259.
87. Hutcheson K, Lewin JS, Garden AS, et al. Early experience with IMPT for the treatment of oropharyngeal tumors: acute toxicities and swallowing-related outcomes. *Int J Radiat Oncol Biol Phys*. 2013 Oct 1; 87(2 Suppl):S605.
88. Isacson U, Lennermäs, Grusell E, et al. Comparative treatment planning between proton and x-ray therapy in esophageal cancer. *Int J Radiat Oncol Biol Phys*. 1998 May1;41(2):441-450. Accessed April 5, 2018.
89. Ishikawa H, Hashimoto T, Moriwaki T, et al. Proton beam therapy combined with concurrent chemotherapy for esophageal cancer. *Anticancer Res*. 2015 Mar;35(3):1757-1762. Accessed April 6, 2018.
90. Jiang ZQ, Yang K, Komaki R, et al. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: The MD Anderson experience. *Int J Radiat Oncol Biol Phys*. 2012;83(1):332-339.
91. Jørgensen AYS, Maraldo MV, Brodin NP, et al. The effect on esophagus after different radiotherapy techniques for early stage Hodgki's lymphoma. *Acta Oncolog*. 2013 ;52(7):1559-1565. Accessed April 17, 2018.
92. Kim S, SHen S, Moore DF, et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. *Europ Urol*. 2011 Nov;60(5):908-916. Accessed April 10, 2018.
93. Kollmeier MA, Fidaleo A, Pei X, et al. Favourable long-term outcomes with brachytherapy-based regimens in men ≤ 60 years with clinically localized prostate cancer. *BJU Int*. 2013;111(8):1231-1236.

94. Kotecha R, Yamada Y, Pei X, et al. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. *Brachytherapy*. 2013;12(1):44-49.
95. Koyama S, Tsujii H. Proton beam therapy with high-dose irradiation for superficial and advanced esophageal carcinomas. *Clin Cancer Res*. 2003;9(10 Pt 1):3571-3577.
96. Kozak KR, Kachnic LA, Adams J, et al. Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment. *Int J Radiat Oncol Biol Phys*. 2007;68(5):1557-1566.
97. Lewinshtein D, Gulati R, Nelson PS et al. Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. *BJU International*. 2012;109(5):706-712.
98. Liao Z, Lee JJ, Komaki R, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small cell lung cancer. *J Clin Oncol*. 2018 Jan 2;JCO2017740720 [Epub ahead of print]. Accessed April 6, 2018.
99. Liao ZX, Lee JJ, Komaki R, et al. Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer. *J Clin Oncol*. 2016; 34(15_suppl), 8500. Accessed April 6, 2018.
100. Lin SH, Komaki R, Liao Z, et al. Proton beam therapy and concurrent chemotherapy for esophageal cancer. *Int J Radiat Oncol Biol Phys*. 2012 Jul 1;83(3):e345-351. Accessed April 6, 2018.
101. Lin SH, Merrell KW, Shen J, et al. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. *Radiother Oncol*. 2017 Jun;123(3):376-381. Accessed April 6, 2018.
102. Lumbroso-Le Rouic L, Delacroix S, Dendale R, et al. Proton beam therapy for iris melanomas. *Eye*. 2006; 20(12):1300-1305.
103. Luu QT, Loredano LN, Archambeau JO, et al. Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report. *Cancer J*. 2006;12(2):155-159.
104. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med*. 2001;345(10):725-730.
105. MacDonald MW, Liu Y, Moore MG, et al. Acute toxicity in comprehensive head and neck radiation for nasopharynx and paranasal sinus cancers: cohort comparison of 3D conformal proton therapy and intensity modulated radiation therapy. *Radiat Oncol*. 2016;11(32). Accessed April 9, 2018.
106. MacDonald MW, Zolali-Meybodi O, Lehnert SJ, et al. Reirradiation of recurrent and second primary head and neck cancer with proton therapy. *Int J Radiat Oncol Biol Phys*. 2016 Nov 15;96(4):808-819. Accessed April 9, 2018.
107. MacDonald SM, Patel SA, Hickey S, et al. Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. *Int J Radiat Oncol Biol Phys*. 2013 Jul 1;86(3):484-490. Accessed April 5, 2018.
108. Makishima H, Ishikawa H, Terunuma T, et al. Comparison of adverse effects of proton and x-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis. *J Radiat Research*. 2015 May 1;56(3):568-576. Accessed April 5, 2018

109. Maraldo MV, Brodin NP, Aznar MC, et al. Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy. *Radiother Oncol*. 2014 Mar;110(3):441-447. Accessed April 17, 2018.
110. Maraldo MV, Brodin NP, Aznar MC, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. *Ann Oncol*. 2013 Aug;24(8):2113-2118. Accessed April 17, 2018.
111. Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. *Int J Radiat Oncol Biol Phys*. 2010 Mar 1;76(3 S);S10-S19. Accessed April 6, 2018.
112. Mazonakis M, Berris T, Lyraaki E et al. Radiation therapy for stage IIA and IIB testicular seminoma: peripheral dose calculations and risk assessments. *Physics in Medicine and Biology*. 2015;60(6):2375-2390.
113. Mendenhall NP, Hoppe BS, Nichols RC, et al. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2014;88(3):596-602.
114. Mizumota M, Yamamoto Y, Takano S, et al. Long-term survival after treatment of glioblastoma multiforme with hyperfractionated concomitant boost proton beam therapy. *Pract Radiat Oncol*. 2015;5(1):e9-e16.
115. Mohan R, Grosshans D. Proton therapy – present and future. *Adv Drug Deliv Rev*. 2017;109:26-44.
116. Mori S and Chen GTY. Quantification and visualization of charged particle range variations. *Int J Radiat Oncol Biol Phys*. 2008 Sep 1;72(1):268-277. Accessed April 6, 2018.
117. Mori S, Wolfgang J, Lu H-M, et al. Quantitative assessment of range fluctuations in charged particle lung irradiation. *Int J Radiat Oncol Biol Phys*. 2008 Jan 1;70(1):253-261. Accessed April 6, 2018.
118. Moteabbed M, Geyer A, Drenkhahn R, et al. Comparison of whole-body phantom designs to estimate organ equivalent neutron doses for secondary cancer risk assessment in proton therapy. *Phys Med Biol*. 2012;57(2):499-515.
120. Murphy ES, Suh JH. Radiotherapy for vestibular schwannomas: a critical review. *Int J Radiat Oncol Biol Phys*. 2011;79(4):985-997.
119. Moyers MF, Miller DW, Bush DA, et al. Methodologies and tools for proton beam design for lung tumors. *Int J Radiat Oncol Biol Phys*. 2001 Apr 1;49(5):1429-1438. Accessed April 6, 2018.
121. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2018 – March 20, 2018. Breast Cancer. Accessed April 5, 2018.
122. . National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2018 – March 20, 2018. Central Nervous System Cancers. Accessed April 5, 2018.
123. National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2018 – March 16, 2018. Esophageal and Esophagogastric Junction Cancers. Accessed April 5, 2018.
124. National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2018 – February 21, 2018. Non-Small Cell Lung Cancer. Accessed April 6, 2018.
125. National Comprehensive Cancer Network (NCCN) Guidelines Version 2. 2018– March 8, 2018. Prostate Cancer. Accessed April 5, 2018.

126. National Comprehensive Cancer Network (NCCN) Guidelines Version 2. 2018– February 16, 2018. TesticularCancer. Accessed April 5, 2018.
127. National Guideline Clearinghouse (NGC). Guideline summary: Proton beam radiation therapy. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Mar 01. Accessed April 10, 2018.
128. Niedzielski JS, Yang J, Mohan R, et al. Differences in normal tissue response in the esophagus between proton and photon radiation therapy for non-small cell lung cancer using in vivo imaging biomarkers. *Int J Radiat Oncol Biol Phys*. 2017 Nov 15;99(4):1013-1020. Accessed April 6, 2018.
129. Noël G, Feuvret L, Calugaru V et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. *Acta Oncol*. 2005; 44(7):700–708. Accessed May 28, 2017.
130. Patel SH, Want Z, Wong WW, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. *Lancet Oncol*. 2014 Aug;15(9):1027- 1038. Accessed April 9, 2018.
131. Peeler CR, Mirkovic D, Titt U, et al. Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma. *Radiother Oncol*; 2016;121(3):395-401.
132. Phan J, Sio TT, Nguyen TP, et al. Reirradiation of head and neck cancer with proton therapy: outcomes and analyses. *Int J Radiat Oncol Biol Phys*. 2016 Sep 1;96(1):30-41. Accessed April 9, 2018.
133. Plastaras JP, Vogel J, Elmongy H, et al. First clinical report of pencil beam scanned proton therapy for mediastinal lymphoma. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2 Suppl):E497. Accessed April 17, 2018.
134. Prayongrat A, Xu C, Li H, et al. Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience. *Adv Radiat Oncol*. 2017 JulSep;2(3):301-307. Accessed April 6, 2018.
135. Ramakrishna NR, Harper B, Burkavage R, et al. A comparison of brain and hippocampal dosimetry with protons or intensity modulated radiation therapy planning for unilateral glioblastoma. *Int J Radiat Oncol Biol Phys*. 2016;96(2 Suppl):e134-e135.
136. Radiation Therapy Oncology Group (RTOG). RTOG 1308 Protocol Information. Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC.
137. Richie JP. Editorial Comment. Re: Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. *J of Urology*. 2012;188(6):2231-2232.
138. Romesser PB, Cahlon O, Scher E, et al. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. *Radiother Oncol*. 2016 Feb;118(2):286-292. Accessed April 9, 2018.
139. Ronson BB, Schulte RW, Han KP, et al. Fractionated proton beam irradiation of pituitary adenomas. *Int J Radiat Oncol Biol Phys*. 2006;64(2):425-434.
140. Rowe J, Grainger A, Walton L et al. Risk of malignancy after gamma knife stereotactic radiosurgery. *Neurosurgery*. 2007;60(1):60-65.

141. Russo AL, Adams JA, Weyman EA, et al. Long-term outcomes after proton beam therapy for sinonasal squamous cell carcinoma. *Int J Radiat Oncol Biol Phys*. 2016 May 1;95(1):358-376. Accessed April 9, 2018.
142. Sachsman S, Flampouri S, Li Z, et al. Proton therapy in the management of non-Hodgkin lymphoma. *Leuk Lymphoma*. 2015;56(9):2608-2612. Accessed April 17, 2018.
143. Sachsman S, Hoppe BS, Mendenhall NP, et al. Proton therapy to the subdiaphragmatic region in the management of Hodgkin lymphoma. *Leuk Lymphoma*. 2015;56(7):2019-2024. Accessed April 17, 2018.
144. Schild ST, Rule Wg, Ashman JB, et al. Proton beam therapy for locally advanced lung cancer: a review. *World J Clin Oncol*. 2014 Oct 10;5(4):568-575. Accessed April 6, 2018.
145. Sejpal S, Komaki R, Tsao A, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. *Cancer*. 2011 Jan 11;117(13):3004-3013. Accessed April 6, 2018.
146. Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. *JAMA*. 2012;307(15):1611-1620.
147. Shih HA, Arvold ND, Niemierko A, et al. Second tumor risk and projected late effects after proton vs. intensity modulated photon radiotherapy for benign meningioma: a dosimetric comparison. *Int J Radiat Oncol Biol Phys*. 2010;78(3): S272.
148. Shih HA, Sherman JC, Nachtigall LB, et al. Proton therapy for low-grade gliomas: results from a prospective trial. *Cancer*. 2015 Jan 13;121(10):1712-1719. Accessed April 5, 2018.
149. Simone II CB, Kramer K, O'Meara WP et al. Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma. *Int J Radiat Oncol Biol Phys*. 2012;82(1): 242-249.
150. Sio TT, Lin H-K, Shi Q, et al. Intensity modulated proton therapy versus intensity modulated photon radiation therapy for oropharyngeal cancer: first comparative results of patient-reported outcomes. *Int J Radiat Oncol Biol Phys*. 2016 Jul 15;95(4):1107-1114. Accessed April 9, 2018.
151. Slater JD, Rossi Jr. CJ, Yonemoto LT, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. *Int J Radiat Oncol Biol Phys*. 2004 Jun 1;59(2):348-352. Accessed April 10, 2018.
152. Spratt DE, Pei X, Yamada J, et al. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2013;85(3):686-92.
153. Steneker M, Lomax A, Schneider U. Intensity modulated photon and proton therapy for the treatment of head and neck tumors. *Radiother Oncol*. 2006;80(2):263-267.
154. Sugahara S, Oshiro Y, Nakayama H, et al. Proton beam therapy for large hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2010;76(2):460-466.
155. Sugahara S, Tokuyue K, Okumura T, et al. Clinical results of proton beam therapy for cancer of the esophagus. *Int J Radiat Oncol Biol Phys*. 2005;61(1):76-84.
156. Tolz A, Shin N, Mitrou E, et al. Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential. *J Appl Clin Med Physics*; 2015 Sept 8;16(5):167-178: Accessed April 17, 2018.
157. Tommasino F, Durante M. Proton radiobiology. *Cancers*. 2015;7(1):353-381.

158. Travis LB, Curtis RE, Faumeni Jr. JF et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. *J Natl Cancer Inst.* 1997 Oct 1; 89(19): 1429-1439. Accessed May 28, 2017.
159. Travis LB, Curtis RE, Faumeni Jr. JF et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. *J Natl Cancer Inst.* 1997;89(19): 1429-1439.
160. Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. *Int J Radiat Oncol Biol Phys.* 2007 Oct 1;69(2):444-453. Accessed April 10, 2018.
161. Trofimov A, Nguyen PL, Efstathiou JA, et al. Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys.* 2011 Jul 1;80(3):928-937. Accessed April 10, 2018.
162. . Tseng YD, Cutter DJ, Plastaras JP, et al. Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. *Int J Radiat Oncol Biol Phys.* 2017 Nov 15;99(4):825-842. Accessed April 17, 2018.
163. Verma V, Iftekaruddin Z, Badar N, et al. Proton beam radiotherapy as part of comprehensive regional nodal irradiation for locally advanced breast cancer. *Radiother Oncol.* 2017 May;123(2):294-298. Accessed April 5, 2018.
164. Verma V, Simone 2nd CB, and Mishra MV. Quality of life and patient-reported outcomes following proton radiation therapy: a systematic review. *J Natl Cancer Inst.* 2018 Apr 1;110(4):341-353. Accessed April 10, 2018.
165. Wang J, Wei C, Tucker SL, et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. *Int J Radiat Oncol Biol Phys.* 2013 Aug 1;86(5):885-891. Accessed April 6, 2018.
166. Wang XS, Shi Q, Williams LA, et al. Prospective study of patient-reported symptom burden in patients with nonsmall-cell lung cancer undergoing proton or photon chemoradiation therapy. *J Pain Symptom Manage.* 2016 May;51(5):832-838. Accessed April 6, 2018.
167. Travis LB, Fossa SD, Schonfield SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. *J Natl Cancer Inst.* 2005;97(18); 1354-1365.
168. Wilkinson B, Morgan H, Gondi V, et al. Low levels of acute toxicity associated with proton therapy for low-grade glioma: a proton collaborative group study. *Int J Radiat Oncol Biol Phys.* 2016 Oct 1; 96(2S):E135. Accessed April 5, 2018.
169. . Winkfield KM, Gallotto S, Niemierko A, et al. Proton therapy for mediastinal lymphomas: an 8-year single-institution report. *Int J Radiat Oncol Biol Phys.* 2015 Nov 1;93(3 Suppl):E461. Accessed April 17, 2018.
170. Xi M, Xu C, Liao Z, et al. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis. *Int J Radiat Oncol Biol Phys.* 2017 Nov 1;99(3):667-676. Accessed April 6, 2018.
171. Yoon M, Kim D, Shin DH, et al. Inter- and intrafractional movement-induced dose reduction of prostate target volume in proton beam treatment. *Int J Radiat Oncol Biol Phys.* 2008 Jul 15;71(4):1091-1102. Accessed April 10, 2018.

172. Yu JB, Soulos PR, Herrin J et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. *J Natl Cancer Inst.* 2013;105(1):25-32
173. Zacharatos Jarlskog C, Paganetti H. Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age. *Int J Radiat Oncol Biol Phys.* 2008;72(1):228-235.
174. Zelefsky MJ, Pei X, Teslova T, et al. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. *BJU Int.* 2012;110(11):1696-701.
175. Zhang X, Zhao KL, Guerrero TM, et al. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. *Int J Radiat Oncol Biol Phys.* 2008;72(1):278-287.
176. Zietman A. Proton beam and prostate cancer: an evolving debate. *Report of Practical Oncol Radiother.* 2013 Nov-Dec;18(6):338-342. Accessed April 10, 2018.
177. Zietman AI, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. *J Clin Oncol.* 2010 Mar 1;28(7):1106-1111. Accessed April 10, 2018.
178. Zorlu F, Gurkaynak M, Yildiz F et al. Conventional external radiotherapy in the management of clivus chordomas with overt residual disease. *Neurol Sci.* 2000;21(4):203–207.
179. Zurlo A, Lomax A, Hoess A, et al. The role of proton therapy in the treatment of large irradiation volumes: a comparative planning study of pancreatic and biliary tumors. *Int J Radiat Oncol Biol Phys.* 2000;48(1):277-288.